Georgiamune Inc., a Gaithersburg, Md.-based clinical stage biotechnology company working in the fields of oncology and autoimmune diseases, completed a $75M Series A financing.
General Catalyst and Parker Institute for Cancer Immunotherapy (PICI) co-led the round. Mubadala Capital, Alexandria Venture Investments, Catalio Capital Management, CJNV BioVenture, and Verition Fund Management also participated.
Led by Founder and CEO Dr. Samir Khleif, Georgiamune is a clinical stage science and discovery biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. They also announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-122, a dual-functioning monoclonal antibody.
The company will initiate a first-in-human, open-label, phase 1/2 dose-escalation with enrichment and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and antitumor activity of GIM-122 as a single agent in adults with advanced solid malignancies who have failed treatment with a checkpoint inhibitor. Georgiamune plans to initiate its phase 1/2 clinical trial in the second half of 2023 and continue development of its extensive first-in-class pipeline for cancer and autoimmune diseases with high unmet needs.
